Glomerulonephritis is a group of disorders characterized by inflammatory injury to the glomeruli, the microscopic filtering structures of the kidneys. It is not a single disease: the term encompasses conditions caused by deposited immune complexes, antibodies directed against glomerular structures, abnormal complement activation, and inflammation associated with systemic small-vessel disease. Manifestations range from microscopic blood in the urine with preserved kidney function to rapidly progressive kidney failure. Some forms are confined largely to the kidneys, whereas others occur as part of infection, autoimmune disease, or an abnormal antibody-producing cell disorder.
Glomerulonephritis is important because it can cause both reversible acute kidney injury and irreversible chronic kidney disease. Its classification integrates clinical presentation, blood and urine findings, and examination of kidney tissue. Distinguishing the underlying mechanisms is essential: suppressing immunity can be effective in some forms but hazardous when uncontrolled infection is responsible. Modern terminology therefore emphasizes the specific disease and mechanism rather than relying solely on descriptive labels such as “acute,” “chronic,” or “proliferative” nephritis.
Glomerular injury and clinical presentation
Each kidney normally contains hundreds of thousands to more than a million nephrons, with substantial variation between individuals. Each nephron begins with a glomerulus, a tuft of capillaries enclosed by Bowman’s capsule. Blood is filtered across an endothelial layer, the glomerular basement membrane, and specialized epithelial cells called podocytes. Supporting mesangial cells help maintain the capillary network and respond to immune deposits and inflammatory signals. This arrangement permits water and small dissolved substances to enter the forming urine while restricting blood cells and most large proteins.
Inflammatory injury changes both filtration and barrier integrity. Swelling, infiltrating white blood cells, and proliferation of resident cells narrow capillary spaces, reducing the glomerular filtration rate. Damage to capillary walls allows red blood cells and plasma proteins to enter the urine. Retention of sodium and water contributes to edema and hypertension. Reduced kidney function may also cause accumulation of potassium, acids, and nitrogenous waste products. In severe disease, fluid accumulation can produce pulmonary edema, while marked potassium elevation can disturb cardiac conduction.
The classic nephritic syndrome combines hematuria, variable proteinuria, reduced filtration, hypertension, and fluid retention. Urine may appear red, brown, or tea-colored, although visible discoloration is not always present. On microscopy, red cells distorted during passage through the damaged filtration barrier support a glomerular source of bleeding. Red-cell casts form when red cells become incorporated into protein molds within renal tubules and are particularly suggestive of inflammatory renal disease. Their absence does not exclude glomerulonephritis.
The nephritic pattern is distinct from nephrotic syndrome, conventionally defined in adults by heavy protein loss, usually more than 3.5 grams per day, together with hypoalbuminemia and often edema. Nevertheless, the two syndromes overlap. Lupus nephritis, infection-related disease, and membranoproliferative patterns can produce both inflammatory urine findings and nephrotic-range proteinuria. Conversely, many predominantly nephrotic disorders, such as minimal change disease, are not usually classified as inflammatory glomerulonephritis.
The time course is equally variable. Some patients have only persistent microscopic hematuria detected incidentally. Others develop an acute nephritic illness over days or a progressive loss of function over months or years. Rapidly progressive glomerulonephritis denotes a clinical course in which kidney function deteriorates over days to weeks, sometimes extending over several months. The speed of decline describes urgency and severity but does not, by itself, identify the cause.
Immunologic mechanisms
Most forms of glomerulonephritis involve the immune system, but the location and nature of the immune response differ. One major mechanism is deposition or local formation of immune complexes containing antibodies and antigens. These complexes can accumulate in the mesangium or along different surfaces of the glomerular capillary wall. They activate inflammatory pathways and recruit leukocytes, whose enzymes and reactive molecules damage adjacent structures. The relevant antigen may derive from an infection, from the patient’s own tissues, or from an abnormal immunoglobulin.
The position of deposits helps explain the resulting disease pattern. Subendothelial deposits lie between the endothelium and basement membrane, where circulating inflammatory cells have relatively direct access to them. They commonly accompany prominent inflammation and proliferative lesions. Mesangial deposits stimulate mesangial cells and inflammatory signaling within the supporting core of the glomerulus. Subepithelial deposits lie beneath podocytes, on the urinary side of the basement membrane. These often produce marked protein leakage with less direct inflammatory-cell access; the precise response depends on the disease and accompanying lesions.
The complement system links immune recognition to tissue injury. Its classical pathway can be activated by immune complexes, while the lectin and alternative pathways provide additional routes of activation and amplification. Products such as C3a and C5a promote inflammation; terminal complement complexes can injure cells. Abnormal regulation of the alternative pathway can itself become the dominant disease mechanism, rather than merely a response to deposited antibodies. Complement activity may be disturbed by inherited variants, acquired autoantibodies, or interactions between these factors.
A different mechanism operates in anti-glomerular basement membrane disease. Autoantibodies usually recognize a specific region of the alpha-3 chain of type IV collagen. Binding along the basement membrane creates a characteristic linear staining pattern and can initiate severe capillary-wall injury. Because the target is also present in pulmonary alveolar basement membranes, some patients develop bleeding into the lungs. This is an example of directly targeted autoimmunity, rather than the granular deposition pattern typical of many immune-complex disorders.
In pauci-immune glomerulonephritis, little immunoglobulin is detected in kidney tissue despite potentially severe inflammation. Many cases are associated with antineutrophil cytoplasmic antibodies, or ANCA, directed against myeloperoxidase or proteinase 3. Under inflammatory conditions, these antibodies can activate primed neutrophils, promoting endothelial injury, protease release, and further complement activation. Not every patient has detectable ANCA, and a positive blood test must be interpreted in its clinical setting rather than treated as a diagnosis by itself.
Diagnostic investigation and kidney pathology
Investigation establishes whether bleeding and protein loss originate in the glomeruli, measures the severity of kidney dysfunction, and identifies an underlying cause. Clinical assessment considers recent infections, medication exposures, systemic inflammatory symptoms, family history, and the trajectory of kidney function. Skin purpura, joint symptoms, sinus disease, pulmonary bleeding, or signs of a persistent infection can materially change the diagnostic interpretation. Blood in the urine also has nonglomerular causes, including kidney stones, tumors, and urinary tract infection.
Urinalysis combines chemical testing with sediment microscopy. Dipstick positivity for blood requires interpretation because it may reflect intact red cells, free hemoglobin, or myoglobin. Protein excretion is commonly estimated using a urine protein-to-creatinine or albumin-to-creatinine ratio; selected circumstances require timed urine collection. Serum creatinine and its change over time help assess filtration, while potassium, bicarbonate, and albumin characterize consequences of kidney dysfunction and protein loss. Estimated filtration equations are less reliable when creatinine is changing rapidly because they generally assume a near-steady state.
Blood testing is selected according to the suspected mechanism. Common investigations include C3 and C4 concentrations, ANCA, anti-basement-membrane antibodies, antinuclear antibodies, and antibodies to double-stranded DNA. Tests for hepatitis B, hepatitis C, or other infections may be relevant. Blood cultures and cardiac evaluation can be important when infective endocarditis is suspected. Serum and urine studies for monoclonal proteins help identify disorders caused by a single abnormal immunoglobulin. No universal blood-test panel substitutes for clinical interpretation: normal complement does not exclude glomerulonephritis, and low complement is not specific to one disease.
A kidney biopsy often provides the decisive classification. Tissue is examined by light microscopy, immunofluorescence, and electron microscopy. Light microscopy shows cellular proliferation, necrosis, capillary-wall remodeling, crescents, and scarring. Immunofluorescence identifies immunoglobulins, complement components, and light chains, distinguishing granular, linear, and pauci-immune patterns. Electron microscopy localizes deposits and reveals ultrastructural abnormalities that may not be evident by the other methods.
Pathology reports distinguish activity from chronic damage. Necrosis, inflammatory proliferation, and cellular crescents may represent potentially treatable active injury. Global glomerular sclerosis, interstitial fibrosis, and tubular atrophy indicate established tissue loss. “Focal” generally means involvement of fewer than half the sampled glomeruli, while “diffuse” means half or more; “segmental” concerns part of an individual glomerular tuft, and “global” concerns the entire tuft. A biopsy samples only a small part of the kidney, so its interpretation includes sampling limitations and the clinical course.
Immune-complex diseases and infection-related forms
IgA nephropathy is characterized by dominant or codominant mesangial IgA deposition. Its pathogenesis commonly involves galactose-deficient IgA1, antibodies recognizing that abnormal IgA1, formation of circulating immune complexes, and their deposition in the kidney. Visible hematuria may occur during an upper respiratory infection or within a few days of its onset. Other patients present with persistent microscopic hematuria, proteinuria, or established kidney impairment. IgA vasculitis has related kidney pathology but occurs with systemic small-vessel disease, often including palpable purpura, abdominal symptoms, and joint manifestations.
Infection-related glomerulonephritis includes classic poststreptococcal disease as well as nephritis associated with ongoing infection. Poststreptococcal glomerulonephritis typically follows pharyngeal infection by about one to three weeks or skin infection by several weeks. C3 is often reduced and usually returns toward normal within roughly six to eight weeks. Biopsy, when required, commonly shows endocapillary inflammation, prominent C3 staining, and subepithelial “hump-shaped” deposits. The latent interval differs from the near-simultaneous respiratory infection and hematuria often seen in IgA nephropathy.
The broader infection-related category is particularly important in adults. Staphylococcal infections can produce an IgA-dominant glomerulonephritis, often in older people or those with diabetes mellitus. The infection may still be active when kidney disease appears. Infective endocarditis can also cause immune-mediated glomerular injury, sometimes accompanied by low complement or positive ANCA. These overlaps make it unsafe to infer a primary autoimmune disorder from one laboratory result. Identifying and treating the infection is central to management, and immunosuppression has a different risk-benefit balance from that in primary immune disease.
Lupus nephritis is a kidney manifestation of systemic lupus erythematosus. Immune deposits may occur in several glomerular compartments and often stain for multiple immunoglobulins and complement components, producing the “full-house” immunofluorescence pattern. Classification separates mesangial, focal and diffuse proliferative, membranous, and advanced sclerosing lesions. Classes III and IV describe focal and diffuse proliferative disease, respectively, and can produce severe nephritic illness. Class V is a membranous pattern more commonly associated with substantial proteinuria; mixed proliferative and membranous lesions also occur.
Cryoglobulinemic glomerulonephritis is associated with immunoglobulins that precipitate under particular low-temperature laboratory conditions. Mixed cryoglobulinemia may accompany hepatitis C, autoimmune disease, or B-cell disorders. Kidney biopsy often shows a membranoproliferative pattern, and C4 can be markedly reduced. Glomerular disease caused by monoclonal immunoglobulin deposition or related processes may arise even when the responsible cell clone is too small to meet criteria for overt multiple myeloma or lymphoma. The kidney lesion, rather than tumor size alone, determines its clinical significance.
Membranoproliferative patterns and complement-mediated disease
“Membranoproliferative glomerulonephritis,” often abbreviated MPGN, describes a pattern of injury rather than a single cause. The defining features include mesangial expansion, increased glomerular cellularity, and remodeling of capillary walls. On light microscopy, duplicated basement-membrane contours may produce a “double-contour” or “tram-track” appearance. These changes develop as cells and new basement-membrane material become interposed along injured capillary walls. Similar architecture can result from several immunologic mechanisms and, in some circumstances, from nonimmune endothelial injury.
Historically, MPGN was divided into types I, II, and III largely according to the location and appearance of deposits on electron microscopy. This system grouped together diseases with different biological drivers. Contemporary classification places greater emphasis on immunofluorescence: substantial immunoglobulin deposition suggests an immune-complex or monoclonal immunoglobulin-mediated process, whereas strongly dominant C3 staining raises the possibility of a complement-mediated disorder. This distinction directs investigation toward infections, autoimmune disease, abnormal immunoglobulins, or dysregulation of complement.
C3 glomerulopathy encompasses C3 glomerulonephritis and dense deposit disease. The two are distinguished primarily by electron microscopy. Dense deposit disease has highly electron-dense material, classically within the glomerular basement membrane; C3 glomerulonephritis has deposits that do not meet that characteristic pattern. Neither necessarily displays an MPGN appearance on light microscopy. The defining concept is C3-dominant glomerular deposition associated with abnormal control of the alternative complement pathway, after appropriate consideration of competing explanations.
Acquired factors include C3 nephritic factors, autoantibodies that stabilize an alternative-pathway C3 convertase, and antibodies against complement-regulatory proteins. Genetic contributors can involve C3, factor B, factor H, factor I, or complement factor H-related proteins. These findings are heterogeneous: a patient may have an acquired abnormality, an inherited predisposition, both, or neither identifiable by available tests. Serum C3 may be low but can also be normal. Genetic results therefore do not independently establish or exclude the diagnosis.
A difficult boundary exists between resolving infection-related glomerulonephritis and C3 glomerulopathy, because both can produce C3-dominant deposits and subepithelial humps. Persistence of low complement, continuing urinary abnormalities, or progressive kidney dysfunction after the expected recovery period can alter the interpretation. In older adults, a monoclonal immunoglobulin may disturb complement regulation without depositing conspicuously in the glomerulus. Such cases demonstrate why tissue appearance, longitudinal observations, complement studies, and evaluation for an abnormal antibody-producing clone must be considered together.
Crescentic and rapidly progressive glomerulonephritis
A glomerular crescent forms when severe capillary-wall injury allows plasma constituents, including fibrin-related material, to enter Bowman’s space. Parietal epithelial cells proliferate, and macrophages and other inflammatory cells accumulate around the glomerular tuft. Early cellular crescents may evolve into fibrocellular and then fibrous lesions. Extensive crescent formation can compress the tuft and accompany rapid loss of filtration. Crescents are therefore a marker of severe injury, not a diagnosis of a single disease.
The major immunopathologic groups are anti-basement-membrane disease, immune-complex disease, and pauci-immune disease. Severe IgA nephropathy, lupus nephritis, and infection-related glomerulonephritis can all form crescents. In clinical usage, “crescentic glomerulonephritis” often refers to biopsies with crescents in more than half of sampled glomeruli, although smaller proportions can still be clinically important. Rapidly progressive kidney dysfunction and crescentic pathology frequently coincide, but the terms are not interchangeable: one describes a clinical trajectory and the other a tissue lesion.
Anti-glomerular basement membrane disease can present with kidney-limited disease or combined kidney and pulmonary involvement. Lung hemorrhage may cause hemoptysis, breathlessness, and a fall in hemoglobin, but visible coughing of blood is not universal. The name Goodpasture syndrome has historically been used for pulmonary–renal presentations, sometimes inconsistently; identifying anti-basement-membrane antibodies and the characteristic linear kidney staining is more specific. Kidney recovery is strongly influenced by the degree of dysfunction and irreversible damage at presentation.
ANCA-associated vasculitis includes granulomatosis with polyangiitis, microscopic polyangiitis, and eosinophilic granulomatosis with polyangiitis. Their frequency and pattern of kidney involvement differ. Granulomatosis with polyangiitis commonly combines respiratory-tract disease with pauci-immune glomerulonephritis, while microscopic polyangiitis frequently causes kidney and pulmonary capillaritis without the same granulomatous pattern. Renal-limited pauci-immune disease also occurs. Proteinase 3 and myeloperoxidase antibody specificity provides information relevant to phenotype and relapse risk but does not map perfectly onto the named clinical syndromes.
Some patients have both ANCA and anti-basement-membrane antibodies. This double-positive group may present with severe kidney injury resembling anti-basement-membrane disease while retaining a longer-term relapse tendency associated with ANCA disease. Pulmonary–renal syndromes also have nonvasculitic mimics, including infection and other causes of simultaneous pulmonary hemorrhage and kidney injury. Distinguishing these entities depends on the combination of serology, imaging, microbiologic investigation, and tissue findings rather than on the presence of crescents or lung bleeding alone.
Treatment principles and disease-specific therapy
Treatment has two complementary components: limiting the consequences of kidney injury and addressing the initiating disease. Supportive care includes control of blood pressure and fluid overload, management of electrolyte and acid-base abnormalities, and reduction of persistent proteinuria when clinically appropriate. Renin–angiotensin system blockers, including agents such as losartan, reduce intraglomerular pressure and protein loss in many chronic proteinuric conditions. Their use depends on kidney function, potassium concentration, and hemodynamic stability; acute rapidly changing kidney failure presents different circumstances from stable chronic disease.
Sodium-glucose cotransporter 2 inhibitors have become part of kidney-protective treatment for many patients with chronic proteinuric kidney disease, including some without diabetes. Their evidence base concerns defined patient populations and does not make them substitutes for treatment of active inflammatory glomerulonephritis. Dialysis provides temporary or long-term support when kidney failure causes otherwise unmanageable complications, such as severe hyperkalemia, acidosis, fluid overload, or uremic manifestations. It removes retained solutes and fluid but does not directly stop glomerular immune injury.
Disease-directed immunosuppressive treatment varies substantially. Proliferative lupus nephritis commonly involves glucocorticoids combined with agents such as mycophenolate or cyclophosphamide, followed by maintenance treatment; selected regimens incorporate belimumab or a calcineurin inhibitor. Severe ANCA-associated disease is commonly treated with rituximab or cyclophosphamide together with glucocorticoid-based treatment, with steroid-sparing approaches available in defined settings. Avacopan, which blocks the C5a receptor, provides one mechanism-specific option in ANCA-associated vasculitis. These regimens carry differing risks of infection, cytopenia, reproductive toxicity, and metabolic complications.
Anti-basement-membrane disease is generally treated using a combination of plasma exchange, glucocorticoids, and cyclophosphamide in appropriate patients. Plasma exchange, a form of apheresis, removes circulating pathogenic antibodies, while immunosuppression reduces further antibody production and inflammation. Its role is not identical across diseases. In the 2020 PEXIVAS trial, routine plasma exchange did not significantly reduce the combined outcome of death or end-stage kidney disease in severe ANCA-associated vasculitis overall. Subsequent clinical interpretation has therefore distinguished selected high-risk circumstances from indiscriminate use.
Infection-related disease requires pathogen-directed treatment and control of the infectious source; immunosuppression is not routine simply because the biopsy shows inflammation. Cryoglobulinemic disease associated with hepatitis C may require antiviral treatment, with additional immune-directed therapy in severe presentations. Monoclonal immunoglobulin-associated disease may require treatment directed at the responsible plasma-cell or B-cell clone. In IgA nephropathy, kidney-protective care, targeted-release budesonide, selected systemic immunosuppression, and newer pathway-directed therapies occupy different roles according to the disease setting. Complement inhibitors likewise have disease- and drug-specific evidence rather than a uniform indication for all complement-positive biopsies.
Epidemiology, prognosis, and transplantation
The epidemiology of glomerulonephritis is difficult to summarize with a single global rate. Studies may count clinically diagnosed nephritic syndromes, biopsy-confirmed diseases, hospital admissions, or causes of kidney failure. Each captures a different population. Kidney-biopsy registries are especially informative for distinguishing subtypes, but their findings depend on access to nephrology, biopsy thresholds, age distribution, and whether patients with mild or very advanced disease undergo tissue sampling. An apparent increase in a diagnosis can therefore reflect changing detection as well as a true change in disease frequency.
IgA nephropathy is among the most frequently identified primary glomerular diseases in many biopsy registries, particularly in parts of East Asia and Europe. Screening practices influence its detection, especially when people with asymptomatic hematuria are investigated. Classic childhood poststreptococcal nephritis has declined in many high-income settings but remains important in populations with a high burden of streptococcal skin and throat infection. In other settings, adult infection-related disease associated with staphylococcal infection and multiple comorbidities constitutes a substantial clinical problem. These patterns should not be treated as fixed biological differences between populations.
Prognosis depends on the specific disease, baseline filtration, proteinuria, blood pressure, response to treatment, and the amount of chronic scarring. Childhood poststreptococcal glomerulonephritis often has a favorable short-term kidney outcome, whereas adult infection-related cases can have substantial persistent impairment. IgA nephropathy ranges from stable urinary abnormalities to progressive kidney failure over decades. Anti-basement-membrane disease can cause abrupt, irreversible injury, particularly when dialysis dependence and extensive destructive lesions are already present. A disease label alone is therefore insufficient to predict an individual course.
Proteinuria and filtration trends are central outcome measures. Persistent protein leakage reflects glomerular barrier damage and can itself contribute to downstream tubular inflammation. Loss of functioning nephrons increases the workload of surviving nephrons, promoting maladaptive hyperfiltration and further scarring. Clinical remission may mean resolution of active urinary findings and stable function, while immunologic remission refers to suppression of the underlying immune process. These states need not occur simultaneously. A fall in circulating antibody concentration, for example, does not reverse established fibrosis.
Kidney transplantation treats irreversible kidney failure but does not invariably eliminate the underlying disease tendency. IgA nephropathy, C3 glomerulopathy, and several immune-complex disorders can recur in the transplanted kidney, with differing effects on graft survival. Anti-basement-membrane disease rarely recurs when transplantation follows sustained disappearance of circulating antibodies. ANCA-associated disease can relapse after transplantation, although modern immunosuppression usually limits its frequency. Recurrence must be distinguished from transplant rejection, drug toxicity, infection, and newly developed glomerular disease in the graft.
Historical development and research directions
The clinical history of glomerulonephritis is closely linked to Richard Bright’s 1827 descriptions connecting edema and albumin in the urine with structural kidney disease. “Bright’s disease” subsequently became a broad label that included several disorders now recognized as distinct. Nineteenth-century microscopy progressively localized disease to different renal compartments, but clinical syndromes remained difficult to separate without reliable tissue sampling. The same combination of swelling, proteinuria, and reduced kidney function could result from markedly different lesions.
Percutaneous kidney biopsy became established during the mid-twentieth century, transforming classification. Immunofluorescence showed that immune deposits could be granular, linear, or nearly absent, while electron microscopy localized deposits within the filtration barrier. These methods converted descriptive clinical syndromes into clinicopathologic diagnoses. Jean Berger and Nicole Hinglais described the characteristic mesangial IgA deposits of IgA nephropathy in 1968. Research into anti-basement-membrane disease subsequently identified the relevant type IV collagen target, providing a direct connection between an autoantibody and a specific structural antigen.
The identification of ANCA and their association with small-vessel vasculitis in the 1980s supplied another mechanistic framework. More recent work connected ANCA-mediated neutrophil activation with alternative complement amplification, helping explain how a disease with few deposited immune complexes could nevertheless respond to complement-pathway intervention. Similarly, recognition of complement dysregulation reorganized parts of the older MPGN classification. These changes illustrate a broader shift from naming the visible lesion to identifying the biological process producing it.
Treatment research has increasingly relied on randomized controlled trials to separate plausible mechanisms from measurable clinical benefit. Rituximab trials in ANCA-associated vasculitis, PEXIVAS, and studies of newer lupus and IgA nephropathy therapies have tested questions that biopsy appearance alone cannot resolve. Trial interpretation depends on which patients were enrolled, background therapy, follow-up duration, and the definition of response. A reduction in proteinuria is valuable but is not identical to demonstrated prevention of kidney failure; filtration preservation and treatment toxicity remain important outcomes.
Current research examines tissue and blood biomarkers, urinary immune signals, complement-function assays, and molecular patterns within individual kidney-cell populations. Genetic studies can identify susceptibility pathways, while spatial and single-cell methods distinguish inflammatory and repair-associated cell states that conventional microscopy groups together. Important unresolved issues include predicting relapse, distinguishing reversible activity from self-sustaining scarring, and selecting patients for targeted treatment without unnecessary immunosuppression. Because many glomerular diseases are uncommon, multinational registries and collaborative trials are particularly important for studying long-term outcomes and less frequent disease subtypes.